{"id":60216,"date":"2024-10-23T07:05:35","date_gmt":"2024-10-23T05:05:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/"},"modified":"2024-10-23T07:05:35","modified_gmt":"2024-10-23T05:05:35","slug":"ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/","title":{"rendered":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer"},"content":{"rendered":"
\n

DAEJEON, South Korea–(BUSINESS WIRE)–#Appointment<\/a>—LigaChem Biosciences, Inc.<\/a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company\u2019s clinical strategy and advancing its robust pipeline of therapeutic candidates.\n<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nDr. Ruiz Soto brings to the table over 20 years of global experience in oncology clinical development, having held senior leadership positions at renowned biopharmaceutical companies. Most recently, he served as Senior Vice President of Clinical Development at Deciphera Pharmaceuticals, where he led the clinical development function and successfully advanced small molecules, including the global approval of Ripretinib. His expertise encompasses a wide range of oncology indications, including solid tumors and hematological malignancies.\n<\/p>\n

\n\u201cRodrigo is an accomplished leader with a proven track record in clinical development,\u201d said Yong-Zu Kim, CEO of LigaChem Biosciences. \u201cHis extensive experience and insights into oncology will be invaluable as we advance our clinical programs and work towards bringing our innovative therapies to market. We are excited to welcome him to the team.\u201d\n<\/p>\n

\nPrior to his role at Deciphera, Dr. Ruiz Soto served as Senior Medical Director at ImmunoGen, Inc., where he was the medical lead for the Mirvetuximab Soravtansine program, which was approved by the FDA in 2022. He also held key positions at Sanofi Oncology, where he oversaw the clinical development of several oncology clinical trials, including a pan-PI3K and mTOR inhibitor.\n<\/p>\n

\n\u201cI am thrilled to join LigaChem Biosciences at such an exciting time in the company\u2019s growth,\u201d said Dr. Ruiz Soto. \u201cI look forward to working with the talented team to advance our promising pipeline and contribute to the development of novel therapies that can make a significant difference in the lives of patients.\u201d\n<\/p>\n

\nDr. Ruiz Soto will officially assume his role as CMO and will be based at AntibodyChem Biosciences, Inc., the company\u2019s US subsidiary in Massachusetts.\n<\/p>\n

\nAbout LigaChem Biosciences<\/b>\n<\/p>\n

\nLigaChem Biosciences is dedicated to the discovery and development of innovative therapies that leverage the power of antibody-drug conjugates to treat cancer and other serious diseases. Our mission is to improve the quality of life for patients by providing effective and targeted treatment options. For more information, visit www.ligachembio.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLigaChem Biosciences
\n
Dae-young Jeong
\n
+82-42-861-0688
\n
jdy@ligachembio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DAEJEON, South Korea–(BUSINESS WIRE)–#Appointment—LigaChem Biosciences, Inc. (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company\u2019s clinical strategy and advancing its robust pipeline … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60216","6":"format-standard","7":"category-industry"},"yoast_head":"\nLigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DAEJEON, South Korea–(BUSINESS WIRE)–#Appointment—LigaChem Biosciences, Inc. (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company\u2019s clinical strategy and advancing its robust pipeline ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-23T05:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer\",\"datePublished\":\"2024-10-23T05:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/\"},\"wordCount\":403,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241022716600\\\/en\\\/2281317\\\/22\\\/official_Dr._Rodrigo_Ruiz_Soto.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/\",\"name\":\"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241022716600\\\/en\\\/2281317\\\/22\\\/official_Dr._Rodrigo_Ruiz_Soto.jpg\",\"datePublished\":\"2024-10-23T05:05:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241022716600\\\/en\\\/2281317\\\/22\\\/official_Dr._Rodrigo_Ruiz_Soto.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241022716600\\\/en\\\/2281317\\\/22\\\/official_Dr._Rodrigo_Ruiz_Soto.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend","og_description":"DAEJEON, South Korea–(BUSINESS WIRE)–#Appointment—LigaChem Biosciences, Inc. (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company\u2019s clinical strategy and advancing its robust pipeline ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-23T05:05:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer","datePublished":"2024-10-23T05:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/"},"wordCount":403,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/","name":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg","datePublished":"2024-10-23T05:05:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241022716600\/en\/2281317\/22\/official_Dr._Rodrigo_Ruiz_Soto.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ligachem-biosciences-appoints-rodrigo-ruiz-soto-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60216"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60216\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}